SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation (www.epeiusbiotech.com) today announces the clinical results of the study entitled “A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol” at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.
SUMMARY: Rexin-G and Reximmune-C are tumor-targeted retrovectors bearing a cytocidal anti-cyclin G1 construct and a controllable GM-CSF expression construct, respectively. The working hypothesis underlying this two-tier complementary approach to tumor eradication and cancer vaccination is that a personalized vaccination of a patient against his or her own specific cancer can be achieved by combining (1) a targeted vector bearing a tumoricidal payload, i.e. Rexin-G, with (2) a targeted vector bearing a potent immuno-stimulatory (GM-CSF) gene, i.e. Reximmune-C. In this model, Rexin-G is first administered to control tumor growth and expose neoantigens within the tumor microenvironment, followed by defined pulses of Reximmune-C, intended to recruit the patient’s immune cells into these lesions, thereby prompting immunologic activation, recognition of tumor neoantigens, and induction of a beneficial antitumor immunity. The initial results of a Phase I/II dose escalation study showed that, in addition to the expected tumoricidal effects of Rexin-G, histopathologic examination of biopsied tumors from patients with a diversity of cancer types revealed targeted nanoparticle delivery, GM-CSF transgene expression, and localized immune responses within the lesions. Importantly, no circulating GM-CSF protein was detected and no dose limiting toxicity was observed throughout the treatment period. Moreover, there appears to be a significant survival benefit which suggests that this two-tier approach has considerable merit as a therapeutic vaccine.
About Epeius Biotechnologies:
Epeius Biotechnologies Corporation (www.epeiusbiotech.com) is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products, Rexin-G and Reximmune-C, and its high-performance gene delivery systems. To learn more about these agents and/or ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon @ epeiusbiotech.com .
News Source: Epeius Biotechnologies Corporation :: This press release was issued by Send2Press® and is Copyright © 2010 Neotrope® News Network – all rights reserved.
Repost This Press ReleaseMore Information:
The visionary business builders of Epeius Biotechnologies Corporation share an abiding passion for the pursuit of excellence in science focused sharply on the development of superior medicines for cancer. Founded in 2000, and incubated at The University of Southern California School of Medicine, Epeius Biotech emerged in 2002 as a free standing company with an enviable IP portfolio, a high-value tumor-targeting platform and lead product that has been validated in the crucible of clinical medicine, and revenues beginning in 2006. Epeius Biotechnologies is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems and high-value oncology products. Credited with innovations ranging from gene discovery, therapeutic designer genes, pathotropic (disease-seeking) targeting, high-performance vector engineering, to advanced GMP & Bioprocess development, Epeius is an acknowledged leader in the field of genetic medicine with an impressive intellectual property estate. Rapid advances in clinical development have provided Epeius with a unique opportunity for early revenues from the exportation and sale of its lead product to the Philippines and reciprocating Southeast Asian countries, thus demonstrating the high-growth potential of an innovative biotechnology company while maintaining the lowered risk profile of a biopharmaceutical company with a high-value, late-stage product.
- Epeius Biotechnologies’ REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA
- Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy
- To Reach, Perchance to Kill the Cancer: A Soliloquy from Epeius Nanotechnologies Opposes that ‘Sea of Troubles’
- Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate with Additional U.S. Patents
- Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010)
Follow Send2Press on Social Media
Stay up to date with Send2Press on popular social portals.